Everything below concerns gastric juice protein. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
A few locals, most notably Arkansas Gazette columnist John Brummett, also objected to the staging of a violent picture at their State Capitol, but the venue did close for filming during the second weekend of September. In a bizarre coincidence, one of its own Magnolia trees burned down during the staging of the helicopter crash. McCuen ordered that the hole be covered to conceal the mishap before it reopened to the public. Principal photography belatedly ended on September 26, 1990. However, more reshoots had to be staged in early 1991 in Los Angeles. Estimates of the film's final budget have varied. Wichard quoted it as $17 million after the mid-production reboot, but $25 million before launch. However, a Stonebridge executive reiterated at the same time that the cost-conscious production had been capped to $17 million. In August 1991, Epic Productions sued producer Yoram Ben Ami for $8 million, accusing him of being responsible for many of the film's creative and logistical woes, resulting in cost overruns that took it from a projected $7 million budget to more than $15 million. The outcome of the lawsuit was not publicized.
=== The TRAIL gene as a drug target === TIC10 (which causes expression of TRAIL) was investigated in mice with various tumour types. Small molecule ONC201 causes expression of TRAIL which kills some cancer cells.
The patient is immunocompromised (for example, in AIDS or after chemotherapy); The infectious agent is of an uncommon nature (e.g. tropical diseases); The disease has not responded to first line antibiotics; The disease might be dangerous to other patients, and the patient might have to be isolated
=== Determining the time of divergence in phylogenetic trees === The molecular clock hypothesis predicts that the rate of amino acid substitution in a particular protein will be approximately constant over time, though this rate may vary between protein families. This suggests that the number of mutations per amino acid in a protein increases approximately linearly with time. Determining the time at which two proteins diverged is an important task in phylogenetics. Fossil records are often used to establish the position of events on the timeline of the Earth's evolutionary history, but the application of this source is limited. However, if the rate at which the molecular clock of protein family ticks — that is, the rate at which the number of mutations per amino acid increases — is known, then knowing this number of mutations would allow the date of divergence to be found. Suppose the date of divergence for two related proteins, taken from organisms living today, is sought. The two proteins have both been accumulating accepted mutations since the date of divergence, and so the total number of mutations per amino acid separating them is approximately twice that which separates them from their common ancestor. If a range of PAM matrices are used to align two proteins that are known to be related, then the value of
The third generation of the Familia Presto was announced in September 1973, a month before the 1973 oil crisis. It was basically an updated version of the 1970 Familia Presto, reintroduced with 60 mm wider bodywork and reworked front and rear designs. It was promoted and marketed as the "Widebody" in Japan. These changes were made only to the saloons and coupé, while the van/wagon and pickups remained in production and retaining the original narrower bodywork with minor changes. The Familia Presto continued using the "Mazda 1000/1300" name in most export markets, "Mazda Marella" name was also retained in Finland. The Rotary Presto saloon/coupé was discontinued in Japan, having been replaced by the larger Grand Familia-based Mazda Savannah. The piston-engined 1000/1300 and rotary-engined R100 coupés were also replaced by 808/818/RX-3 coupé for export market. This generation was not available in North America and replaced by the bigger 808/Mizer/RX-3. Developed to meet new stricter emissions standards in the domestic market, the Presto featured the 1272 cc TC engine or the by now familiar, pushrod 1.0-litre PB unit. Power outputs in Japan (JIS gross) are 62 PS (46 kW; 61 hp) and 87 PS (64 kW; 86 hp) respectively, 50 PS (37 kW; 49 hp) and 66 PS (49 kW; 65 hp) (DIN) for export markets. Production of the third generation Familia ended in January 1977, but not before another minor facelift and emissions scrubbing had taken place in February 1976. This changes were not applied for export market.
Sources: en.wikipedia.org
Once a sequence has been isolated, it must be inserted into a vector. The easiest way to do this is to cut the vector DNA using restriction enzymes; if the same enzymes were used to isolate the target sequence, then the same "overhang" sequences will be created on each end allowing for hybridization. Once the target gene has hybridized to the vector DNA, they can be joined using a DNA ligase. An alternative strategy uses recombination between homologous sites on the target gene and the vector sequence, eliminating the need for restriction enzymes.
DMT is inactive when ingested orally due to metabolism by monoamine oxidase (MAO), and DMT-containing drinks such as ayahuasca have been found to contain monoamine oxidase inhibitors (MAOIs), in particular, harmine and harmaline. Life-threatening lethalities such as serotonin syndrome (SS) may occur when MAOIs are combined with certain serotonergic medications such as selective serotonin reuptake inhibitor (SSRI) antidepressants. Serotonin syndrome has also been reported with tricyclic antidepressants (TCAs), certain opioids, certain analgesics, and antimigraine drugs; it is advised to exercise caution when an individual has used dextromethorphan (DXM), MDMA, ginseng, or St. John's wort recently. Chronic use of SSRIs, TCAs, and MAOIs diminish subjective effects of psychedelics due to presumed serotonin 5-HT2A receptors downregulation and/or desensitization secondary to elevated serotonin levels. However, a clinical study of people with depression found that SSRIs did not diminish the effects of DMT and instead resulted in greater mystical experience, emotional breakthrough, and ego dissolution scores with DMT than in people with depression not on antidepressants. This was in contrast to previous research finding that SSRIs diminished the effects of serotonergic psychedelics. The interaction between psychedelics and antipsychotics and anticonvulsants are not well documented; however, reports reveal that co-use of psychedelics with mood stabilizers such as lithium may provoke seizure and dissociative effects in individuals with bipolar disorder.
=== Zinc world === Armen Mulkidjanian's zinc world (Zn-world) hypothesis extends Wächtershäuser's pyrite hypothesis. The Zn-world theory proposes that hydrothermal fluids rich in H2S interacting with cold primordial ocean (or Darwin's "warm little pond") water precipitated metal sulfide particles. Oceanic hydrothermal systems have a zonal structure reflected in ancient volcanogenic massive sulfide ore deposits. They reach many kilometers in diameter and date back to the Archean. Most abundant are pyrite (FeS2), chalcopyrite (CuFeS2), and sphalerite (ZnS), with additions of galena (PbS) and alabandite (MnS). ZnS and MnS have a unique ability to store radiation energy, e.g. from ultraviolet light. When replicating molecules were originating, the primordial atmospheric pressure was high enough (>100 bar) to precipitate near the Earth's surface, and ultraviolet irradiation was 10 to 100 times more intense than now; hence the photosynthetic properties mediated by ZnS provided the right energy conditions for the synthesis of informational and metabolic molecules and the selection of photostable nucleobases. The Zn-world theory has been filled out with evidence for the ionic constitution of the interior of the first protocells.
In 2022, László Németh founded LiLiChro, where he continued his research on better and more efficient cells. His team is currently working on 2 more patents, further strengthening the position of CPC in chromatography.
The M80 Stiletto is an American prototype naval ship using advanced stealth technologies. The M80 was designed by the M Ship Company then built by Knight and Carver, as an experimental testbed ship for The Pentagon’s Office of Force Transformation. It is notable for its innovative pentamaran hull design and advanced carbon fiber composite construction. The multihull uses its width to gain stability. Its five slim hulls create virtually no bow wave, thus obviating the "hull speed' limitation of displacement craft. The Stiletto's "double-M hull" enables the craft to achieve a remarkably steady ride in rough seas at high speed. A disadvantage is that the five hulls give a large "wetted area", increasing drag.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.